Lymph node (LN) metastasis is a sign that things are going from bad to worse in cancer patients, and prompt treatment is vital.
A research team from Tohoku University’s Graduate School of Biomedical Engineering has developed a lymphatic drug delivery system (LDDS), where anticancer drugs are injected directly into the metastatic LNs. When combined with total-body irradiation (TBI), the new LDDS has a superior antitumor effect than conventional chemotherapy on early stage LN metastasis.
TBI provides a uniform dose of radiation to the entire body, penetrating areas in which traditional chemotherapy cannot reach. Recently, TBI has shown positive results in activating immune responses and altering the tumor microenvironment. Meanwhile, LDDS is mainly used for treating metastatic LNs locally.
The research team hoped to widen LDDS’s usage to prevent distant metastases – where the cancer spreads from the primary tumor to a distant lymph node. “We knew a combination of treatment that enhances systemic tumor immune effects would be an important therapeutic strategy,” said graduate student Shota Sora, who was part of the research team headed by Professor Tetsuya Kodama.
Sora and his colleagues investigated the dual therapy of LDDS and TBI for LN and distant metastases on metastasis model mice. They used irradiation gamma rays (a onetime dose of 1.0 GY) and anticancer drug CDDP adjusted with a solvent to have an osmotic pressure of 1987 kPa and a viscosity of 11.3 mPas.
An in vivo bioluminescence imaging system, a high frequency ultrasound system, and histology showed the new therapy was more effective than employing LDDS or TBI alone. After the therapy, the expression of immune-response related genes (CD4, CD8, and IL-12b) increased in the spleen, indicating an activated immune response.
- Publication Details:
Title: Combination therapy of lymphatic drug delivery and total-body irradiation in metastatic lymph node and lung mouse model
Authors: Sora Shouta, Sukhbaatar Ariunbuyan, Fukushige Shinichi, Sakamoto Maya, Mori Shiro, and Kodama Tetsuya
Journal: Cancer Science
DOI: 10.1111/cas.15562
